PSTV - Plus Therapeutics Inc Stock Price, Fair Value and News

2.16USD0.00 (0.00%)Delayed as of 13 May 2024, 01:03 pm ET

Market Summary

USD2.160.00

Delayedas of 13 May 2024, 01:03 pm

0.00%

PSTV Alerts

5 major insider buys recently.

PSTV Stock Price

View Fullscreen

PSTV RSI Chart

PSTV Valuation

Market Cap

9.2M

Price/Earnings (Trailing)

-0.69

Price/Sales (Trailing)

30.34

Price/Free Cashflow

-0.72

PSTV Price/Sales (Trailing)

PSTV Profitability

Return on Equity

987.83%

Return on Assets

-116.93%

Free Cashflow Yield

-139.14%

PSTV Fundamentals

PSTV Revenue

Revenue (TTM)

303.0K

PSTV Earnings

Earnings (TTM)

-13.3M

Earnings Growth (Yr)

32.66%

Earnings Growth (Qtr)

-18.36%

Breaking Down PSTV Revenue

52 Week Range

1.124.45

(Low)(High)

Last 7 days

24.4%

Last 30 days

21.7%

Last 90 days

13.7%

Trailing 12 Months

-54.4%

How does PSTV drawdown profile look like?

PSTV Financial Health

Current Ratio

0.92

Debt/Equity

-2.91

Debt/Cashflow

-3.41

PSTV Investor Care

Shares Dilution (1Y)

82.69%

Diluted EPS (TTM)

-4.32

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2020	0	0	0	303.0K
2019	2.8M	0	2.4M	3.2M
2018	3.6M	4.0M	3.1M	3.0M
2017	6.2M	5.0M	4.4M	3.7M
2016	6.7M	6.6M	6.7M	6.7M
2015	4.8M	5.7M	6.9M	6.0M
2014	6.0M	6.1M	5.0M	5.0M
2013	9.6M	8.5M	8.8M	7.3M
2012	8.1M	7.6M	6.8M	8.7M
2011	6.8M	7.1M	8.3M	8.0M
2010	0	8.5M	8.1M	7.7M
2009	0	0	0	8.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Plus Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 08, 2024	clowes howard	bought	20,000	2.04	9,804	-
May 08, 2024	sims andrew john hugh macintyre	bought	10,000	2.04	4,902	chief financial officer
May 08, 2024	petersen greg	bought	25,000	2.04	12,255	-
May 08, 2024	hedrick marc h	bought	25,000	2.04	12,255	chief executive officer
May 08, 2024	hawkins richard j	bought	10,000	2.04	4,902	-
May 08, 2024	lenk robert p	bought	8,500	2.04	4,167	-
Nov 20, 2023	hedrick marc h	sold	-4,052	1.9597	-2,068	chief executive officer
Nov 16, 2023	lenk robert p	bought	1,950	1.95	1,000	-
Nov 15, 2023	lenk robert p	bought	1,770	1.77	1,000	-
Nov 13, 2023	lenk robert p	bought	5,720	1.43	4,000	-

Which funds bought or sold PSTV recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	JPMORGAN CHASE & CO	added	1.01	4.00	181	-%
May 10, 2024	VANGUARD GROUP INC	unchanged	-	1,787	58,737	-%
May 10, 2024	BlackRock Inc.	unchanged	-	382	12,563	-%
May 10, 2024	OSAIC HOLDINGS, INC.	unchanged	-	8.00	240	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	unchanged	-	2.00	63.00	-%
May 10, 2024	GROUP ONE TRADING, L.P.	unchanged	-	-	2.00	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Feb 14, 2024	CITADEL ADVISORS LLC	new	-	30,142	30,142	-%
Feb 14, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-26,464	-	-%
Feb 13, 2024	RENAISSANCE TECHNOLOGIES LLC	new	-	58,000	58,000	-%

Are Funds Buying or Selling PSTV?

Are funds buying PSTV calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PSTV

No. of Funds

PSTV Alerts

5 major insider buys recently.

Unveiling Plus Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2023	parkman healthcare partners llc	1.7%	583,467	SC 13G/A
Feb 11, 2022	intracoastal capital, llc	1.9%	3e+05	SC 13G/A
Feb 04, 2022	parkman healthcare partners llc	7.4%	1,508,508	SC 13G
Feb 04, 2022	hudson bay capital management lp	3.46%	550,000	SC 13G/A
Feb 26, 2021	nanotx, corp.	4.83%	230,769	SC 13G/A
Feb 26, 2021	nanotx, corp.	4.83%	230,769	SC 13G/A
Feb 10, 2021	hudson bay capital management lp	9.99%	530,474	SC 13G/A
Jan 29, 2021	intracoastal capital, llc	5.9%	3e+05	SC 13G/A
May 14, 2020	nanotx, corp.	5.61%	230,769	SC 13G
Feb 14, 2020	anson funds management lp	4.9%	198,034	SC 13G/A

Recent SEC filings of Plus Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 09, 2024	8-K	Current Report
Mar 14, 2024	8-K	Current Report
Mar 13, 2024	8-K	Current Report
Mar 08, 2024	S-1/A	Initial Public Offering

Peers (Alternatives to Plus Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.0B	6.8B	9.94%	-6.22%	-7.88	6.87	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	-2.91%	-28.25%	-57.66	9.56	75.20%	68.82%
BMRN	15.5B	2.5B	-8.16%	-14.11%	75.52	6.28	13.74%	186.89%
INCY	12.0B	3.8B	-3.25%	-16.30%	16.12	3.19	8.58%	129.81%
MID-CAP
BBIO	5.4B	107.9M	1.06%	107.74%	-9.96	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-22.86%	-53.47%	-12.21	9.72	394.93%	39.61%
AXSM	3.4B	251.0M	1.43%	-8.15%	-11.62	13.72	73.58%	-86.73%
ARWR	2.7B	240.7M	-5.83%	-38.95%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-16.20%	-29.75%	-1.5K	3.1	56.43%	98.83%
SMALL-CAP
CPRX	1.8B	411.3M	-0.89%	-10.62%	28.39	4.49	60.38%	-34.49%
NVAX	627.6M	996.6M	1.13%	-50.28%	-1.57	0.63	-26.66%	65.49%
CRBP	467.4M	881.7K	16.73%	369.82%	-13.85	481.06	-77.61%	33.36%
INO	261.3M	4.9M	-3.87%	15.02%	-1.93	53.69	-54.97%	51.71%
IBIO	6.6M	2.1M	-13.36%	77.36%	-0.24	2.14	-13.45%	66.37%

Plus Therapeutics Inc News

Latest updates

Plus Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2020Q4	2019Q4	2019Q3	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1	2016Q4	2016Q3	2016Q2	2016Q1	2015Q4	2015Q3	2015Q2	2015Q1	2014Q4
Revenue	-100.0%	-	1,188	526	737	713	454	899	917	867	1,306	531	1,018	1,561	1,879	1,699	1,585	1,556	1,711	1,847	902	2,469
Gross Profit	-	-	-	-	-	-	230	30.00	152	29.00	-20.00	262	-125	521	113	541	766	765	264	318	305	1,053
Operating Expenses	-0.2%	3,395	3,401	2,091	2,903	2,578	2,681	2,745	3,787	-	-	-	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	-53.9%	2,299	4,985	94.00	114	47.00	118	185	294	-	-	-	-	-	-	-	-	-	-	-	-	-
R&D Expenses	-36.6%	1,096	1,729	921	1,426	1,636	1,226	1,267	1,395	-4,211	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-39.3%	229	378	366	515	543	513	444	423	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-505.8%	-3,587	884	526	-3,150	-2,236	-2,330	-3,659	-4,409	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income Margin	-Infinity%	-27.20*	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-Infinity%	-3,238	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-14.2%	11,388	13,278	14,197	15,638	23,867	23,104	21,271	24,516	21,981	24,750	20,834	18,336	12,105	11,653	13,904	20,967	23,229	25,715	8,884	24,616	23,991
Current Assets	-15.1%	9,834	11,584	12,364	13,629	21,817	20,879	18,889	22,104	19,724	22,097	18,001	15,446	9,175	8,649	10,793	17,697	19,825	22,264	5,260	8,462	9,648
Cash Equivalents	-22.3%	8,554	11,006	10,895	12,723	18,120	20,266	18,090	21,239	18,400	21,280	17,161	14,447	8,346	7,626	9,266	16,061	17,552	16,834	4,530	3,872	5,261
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	107	107	107	107	107	107	107	107
Net PPE	-10.2%	906	1,009	1,143	1,276	1,324	1,453	1,560	1,558	1,477	1,646	1,738	1,825	1,820	1,943	2,014	2,096	2,179	2,209	2,297	2,384	2,299
Goodwill	0%	372	372	372	372	372	372	372	372	372	372	372	372	372	372	372	372	372	372	372	372	372
Liabilities	19.5%	12,736	10,656	11,535	12,962	17,422	11,700	11,592	9,874	11,145	9,995	8,889	8,823	9,074	9,032	10,604	20,882	22,069	25,555	15,160	20,759	18,766
Current Liabilities	1.8%	10,727	10,538	11,399	12,796	11,852	7,420	6,971	4,921	5,870	9,488	8,354	8,315	8,539	8,404	9,773	14,988	14,486	14,427	13,923	18,295	17,559
Long Term Debt	-	-	-	-	-	3,786	4,108	4,419	4,718	5,005	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Current	-8.6%	3,976	4,348	4,709	5,057	1,608	1,608	1,608	1,608	1,608	6,752	6,618	6,486	6,335	6,181	6,026	11,182	11,060	10,937	10,813	14,371	14,202
LT Debt, Non Current	-	-	-	-	-	3,786	4,108	4,419	4,718	5,005	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-151.4%	-1,348	2,622	2,662	2,676	6,445	11,404	9,679	14,642	10,836	14,755	11,945	9,513	3,031	2,621	3,300	85.00	1,160	160	-	3,857	5,225
Retained Earnings	-0.8%	-480,501	-476,700	-473,472	-471,990	-467,185	-461,527	-456,300	-451,026	-446,910	-442,755	-439,000	-436,231	-433,511	-429,924	-428,196	-426,357	-425,270	-426,154	-426,680	-417,533	-414,383
Additional Paid-In Capital	0.0%	479,274	479,308	476,131	474,630	473,628	472,899	465,965	465,646	457,730	457,495	450,964	445,734	436,535	432,540	431,492	426,438	426,426	426,311	420,404	420,312	418,390
Accumulated Depreciation	-	2,536	-	-	-	1,960	-	-	-	1,415	-	-	-	1,387	-	-	-	1,021	-	-	-	662
Shares Outstanding	0%	4,523	4,523	2,880	2,408	2,240	1,586	1,484	1,434	1,034	731	753	551	450	293	264	-	-	-	-	-	-
Float	-	-	-	5,800	-	-	-	12,100	-	-	-	30,800	-	-	-	5,400	-	-	-	5,400	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	20.6%	-1,881	-2,370	-2,807	-5,793	-2,234	-4,222	-2,640	-3,876	-2,624	-2,251	-2,399	-3,006	-3,224	-2,299	-1,409	-1,502	1,036	-2,522	-1,150	-3,270	-2,488
Share Based Compensation	-4.7%	141	148	140	140	130	129	167	180	181	180	138	107	98.00	94.00	43.00	12.00	21.00	29.00	28.00	49.00	30.00
Cashflow From Investing	-320.0%	-42.00	-10.00	-11.00	-97.00	-11.00	-33.00	-138	-577	2.00	-4.00	4.00	-84.00	-56.00	-14.00	-412	-11.00	-59.00	-2.00	5,637	-6.00	-5.00
Cashflow From Financing	-121.0%	-529	2,520	961	493	99.00	6,431	-371	7,292	-258	6,374	5,109	9,191	4,000	673	-4,974	-18.00	-259	14,424	-3,425	1,891	922

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PSTV Income Statement

2023-12-31

STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 9,690	$ 9,698
General and administrative	8,544	10,238
Total operating expenses	18,234	19,936
Operating loss	(13,321)	(19,712)
Other income (expense):
Interest income	400	147
Interest expense	(395)	(711)
Change in fair value of liability instruments		1
Total other income (expense)	5	(563)
Net loss	$ (13,316)	$ (20,275)
Net loss per share, basic	$ (4.24)	$ (11.58)
Net loss per share, diluted	$ (4.24)	$ (11.58)
Basic weighted average shares used in calculating net loss per share attributable to common stockholders	3,140,925	1,750,350
Diluted weighted average shares used in calculating net loss per share attributable to common stockholders	3,140,925	1,750,350
Grant [Member]
Revenue	$ 4,913	$ 224

PSTV Balance Sheet

2023-12-31

BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 8,554	$ 18,120
Other current assets	1,280	3,697
Total current assets	9,834	21,817
Property and equipment, net	906	1,324
Operating lease right-use-of assets	202	248
Goodwill	372	372
Intangible assets, net	42	94
Other assets	32	12
Total assets	11,388	23,867
Current liabilities:
Accounts payable and accrued expenses	6,631	10,134
Operating lease liability	120	110
Term loan obligation, current	3,976	1,608
Total current liabilities	10,727	11,852
Noncurrent operating lease liability	85	141
Term loan obligation		3,786
Deferred grant liability	1,924	1,643
Total liabilities	12,736	17,422
Commitments and contingencies (Note 6)
Stockholders' equity (deficit):
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 1,952 shares issued and outstanding as of December 31, 2023 and 2022
Common stock, $0.001 par value; 100,000,000 shares authorized; 4,522,656 issued and 4,444,097 outstanding as of December 31, 2023, 2,240,092 shares issued and outstanding as of December 31, 2022, respectively	5	2
Treasury stock (at cost, 78,559 shares as of December 31, 2023)	(126)
Additional paid-in capital	479,274	473,628
Accumulated deficit	(480,501)	(467,185)
Total stockholders' equity (deficit)	(1,348)	6,445
Total liabilities and stockholders' equity (deficit)	$ 11,388	$ 23,867

About Plus Therapeutics Inc

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186Re obisbemeda, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

CEO	Dr. Marc H. Hedrick M.B.A., M.D.
WEBSITE	https://plustherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	17

Plus Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Plus Therapeutics Inc? What does PSTV stand for in stocks?

PSTV is the stock ticker symbol of Plus Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Plus Therapeutics Inc (PSTV)?

As of Fri May 10 2024, market cap of Plus Therapeutics Inc is 9.24 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PSTV stock?

You can check PSTV's fair value in chart for subscribers.

What is the fair value of PSTV stock?

You can check PSTV's fair value in chart for subscribers. The fair value of Plus Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Plus Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PSTV so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Plus Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether PSTV is over valued or under valued. Whether Plus Therapeutics Inc is cheap or expensive depends on the assumptions which impact Plus Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PSTV.

What is Plus Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 10 2024, PSTV's PE ratio (Price to Earnings) is -0.69 and Price to Sales (PS) ratio is 30.34. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PSTV PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Plus Therapeutics Inc's stock?

In the past 10 years, Plus Therapeutics Inc has provided -0.595 (multiply by 100 for percentage) rate of return.